Rosetta Genomics Ltd. engages in the provision of therapeutic, diagnostic product development, and medical research services. The firm is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY, and RosettaGX Reveal. The firm's therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. The firm focuses on developing a diagnostic assay, RosettaGX Reveal V2. The company is also focusing on developing Bladder cancer risk stratification.
Follow-Up Questions
What is Rosetta Genomics Ltd (ROSGQ)'s P/E Ratio?
The P/E ratio of Rosetta Genomics Ltd is 0
What is the price performance of ROSGQ stock?
The current price of ROSGQ is $0.0001, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Rosetta Genomics Ltd?
Rosetta Genomics Ltd belongs to Biotechnology industry and the sector is Health Care
